.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,792,795

« Back to Dashboard
Patent 5,792,795 protects EPANOVA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 5,792,795

Title: Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Abstract:Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).
Inventor(s): Buser; Thomas (Ziefen, CH), Camporesi; Emilio P. (Ziefen, CH)
Assignee: Tillotts Pharma AG (Ziefen, CH)
Application Number:08/687,329
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 7th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYes5,792,795► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,792,795

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9509764May 15, 1995
PCT Information
PCT FiledMay 13, 1996PCT Application Number:PCT/EP96/02038
PCT Publication Date:November 21, 1996PCT Publication Number: WO96/36329

Non-Orange Book Patents for Patent: 5,792,795

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,948,818 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,792,795

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria294575► subscribe
Australia5895596► subscribe
Australia702692► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc